Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at TD Cowen

Research analysts at TD Cowen initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report issued on Friday,Briefing.com Automated Import reports. The brokerage set a “buy” rating on the stock.

Several other analysts have also recently commented on DNTH. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer lifted their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Finally, Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Dianthus Therapeutics has an average rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Stock Down 1.0 %

Shares of Dianthus Therapeutics stock opened at $23.04 on Friday. Dianthus Therapeutics has a 12-month low of $7.16 and a 12-month high of $33.77. The firm has a market capitalization of $681.91 million, a PE ratio of -9.22 and a beta of 1.74. The stock’s fifty day moving average is $25.77 and its 200-day moving average is $26.60.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Quest Partners LLC raised its holdings in Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after buying an additional 1,124 shares in the last quarter. SG Americas Securities LLC acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at $112,000. The Manufacturers Life Insurance Company bought a new position in Dianthus Therapeutics in the 2nd quarter worth $236,000. Fred Alger Management LLC lifted its position in Dianthus Therapeutics by 52.5% during the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after acquiring an additional 3,316 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new stake in Dianthus Therapeutics during the second quarter valued at about $265,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.